Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
Novartis Pharmaceuticals
Axel Hauschild; Reinhard Dummer; Dirk Schadendorf; Mario Santinami; Victoria Atkinson; Mario Mandalà; Vanna Chiarion-Sileni; James Larkin; Marta Nyakas; Caroline Dutriaux; Andrew Haydon; Caroline Robert; Laurent Mortier; Jacob Schachter; Thierry Lesimple; Ruth Plummer; Kohinoor Dasgupta; Tomas Haas; Mark Shilkrut; Eduard Gasal; Richard Kefford; John M Kirkwood; Georgina V Long